Rheumatoid arthritis is a highly prevalent inflammatory disease characterised by autoimmune immunological processes. Gout is a commonly occurring metabolic disease associated with systemic hyperuricaemia which only occasionally coexists with rheumatoid arthritis.' The present study was performed to determine whether uric acid modulating effects on rheumatoid inflammatory and autoimmune processes occur, since these effects might help to explain the infrequent simultaneous occurrence of these 2 relatively widespread rheumatological conditions. Uric acid effects on rheumatoid inflammatory processes were examined in an in-vitro system utilising neutrophil monolayers and immunoglobulin G (IgG) aggregates. The effects of uric acid on immunocompetent cells were studied in a system in which cells producing rheumatoid factor (RF) were polyclonally induced by haptenated mononuclear leucocytes.
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Materials and methods
All studies were approved by the institutional clinical research practices committee. Informed consent was obtained from all participating subjects and all research was carried out according to the principles of the Declaration of Helsinki.
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For the neutrophil-aggregate studies normal human polymorphonuclear leucocytes were suspended at 5 x 1 06/ml concentration in Dulbecco's phosphate buffered saline (PBS) containing 10% autologous serum. Monolayers were prepared by placing 2-5 ml of this cell suspension in 35 x 10 mm plastic Petri dishes, incubating them for 45 min at 37°C, and washing gently with room temperature PBS. Cells/monolayer were determined by counting cells/standardised grid under an inverted microscope. 1-5 ml of a solution containing PBS, 10% serum, and either, 0, 4, 8, or 12 mg/dl uric acid (obtained from Fisher Scientific Company) were placed on the freshly prepared cell monolayers, which were then incubated for 30 min at 37°C. The supernatants were then removed, and for the phagocytosis studies 5'Cr-labelled IgG aggregates (2-4 mg/ml) were then added to the monolayers,.
which were incubated for 30 min, and cells/monolayer and mg of aggregated IgG/monolayer were then determined by methods previously described.2 For enzyme studies unlabelled IgG aggregates were used, and fluid was aspirated from the monolayers for measurement of supernatant enzyme activity. The cell layer and remaining fluid were detergent-lysed and assayed for enzyme release by standard methods previously described.3
Studies inducing rheumatoid factor producing cells were performed as previously described. lysozyme release under the conditions of our study.
The results of experiments done to determine the effects of increasing concentrations of uric acid on the trinitrophenyl-coupled mononuclear-leucocyteinduced polyclonal activation of lymphocytes to produce rheumatoid factor are shown in Fig. 3 . In these experiments rheumatoid-factor-producing cells were generated after coculturing normal and TNPhaptenated mononuclear leucocytes. Uric acid at a concentration of 4 mg/dl significantly (p<0-01) Uric acid effects on in vitro models ofrheumatoid inflammatory and autoimmune processes 341 increased the numbers of rheumatoid-factorproducing cells detected in these cultures when compared to control cultures without added uric acid.
Cultures containing 8 mg/dl of uric acid were no different from control cultures containing no added uric acid, but cultures containing 12 mg/dl of uric acid had significantly (p<001) less rheumatoid-factorproducing cells than control cultures without added uric acid.
Discussion
These studies suggest that hyperuricaemia does not affect the phagocytosis of IgG aggregates, which has been thought"2 to be an important contributing factor to the inflammation occurring in the joints of patients with rheumatoid arthritis. This finding is in keeping with that of Malawista et al., 3 who reported a similar lack of effect on phagocytosis using uric acid, human neutrophils, and different particles. Their study demonstrated augmented LDH release in the presence of silica crystals but not bacteria. They attributed this augmented release to inhibition by uric acid of the binding of albumin but not IgG to membrane surfaces and subsequent increased susceptibility to crystal-induced phagolysosome lysis and cell death.
We have extended these studies in a system which does not cause early cell death but does result in the selective release of lysosomal enzymes. It is clear from our studies that high levels of uric acid enhance the release of azurophilic granular enzymes. This effect did not seem to be mediated through crystal formation as (1) none were detected by polarised light microscopic examination of test solutions; (2) there was no effect on enzyme release by the highest concentrations of uric acid used alone with the cells; and (3) crystallisation may not be expected to occur under the experimental conditions employed in these studies. '4 15 High levels of uric acid clearly inhibit the ability of our normal mononuclear cell system to be activated to produce rheumatoid factor. This activation may be a model for the response of the rheumatoid patient's immunological system to the factors responsible for the initiation and persistence of the rheumatoid process. This process often results in invasion of cartilage by masses of activated cells and the erosion of cartilage and bone by the rheumatoid pannus. Lussier and deMedicis"6 studied the effects of hyperuricaemia on adjuvant arthritis which had been used as an in-vivo animal model for the study of rheumatoid joint disease processes. Their studies showed weak uric acid effects on the primary inflammatory stage but marked inhibitory effects on the secondary destructive stage of this experimental model. Our studies suggest similar findings with an enhancement of inflammatory but an inhibition of immunological processes by high levels of uric acid. Although there have been a number of recent clinical reports' 17-21 of coexisting gout and rheumatoid arthritis, our study is the first to describe uric acid effects on in-vitro neutrophil and lymphocyte functional systems designed as models of rheumatoid inflammation and autoimmunity. Future clinical studies might prospectively examine the effects of hyperuricaemia on these aspects of rheumatoid disease processes and determine their effects on the x-ray progression which is seen in many patients with rheumatoid arthritis. 
